Introducing clinical intelligence:
Human expertise. Connected data. AI acceleration.
Our technology partners and solutions.
One partnership to deliver better outcomes with ICON’s clinical intelligence ecosystem.
Clinical intelligence. Three pillars. One ecosystem.
-
human expertise
One partnership, bringing 30+ years of expertise at every decision point. -
connected data
We bring diverse data sources together in a structured, interoperable way, underpinned by a robust data foundation to ensure insights can be applied consistently and responsibly. -
aI acceleration
AI ecosystem, powered by Orbis, supporting clinical trial delivery from early design through closeout.
Clinical intelligence vision paper
Discover how clinical intelligence is transforming the way development teams generate insights, manage complexity, and accelerate decision-making across the clinical lifecycle.
Trial initiation
ICON is using and expanding AI supported protocol digitisation and optimisation capabilities to convert protocols into structured data and surface potential operational risks earlier. These approaches help teams identify inconsistencies, reduce patient and site burden, and make more informed design decisions up front, with the aim of reducing amendments and rework downstream.
Trial setup
ICON is using and further developing AI enabled solutions to support feasibility assessment, contracting, and informed consent workflows. This includes the use of precedent based intelligence to assist with contract drafting, as well as automated support for consent documentation updates. These capabilities are designed to reduce manual effort, improve consistency, and support more predictable study activation.
Trial execution
ICON is deploying and expanding AI supported monitoring environments that bring data from multiple systems into more unified workspaces for CRAs and operational teams. These platforms provide contextual protocol guidance, highlight emerging site risks, and support prioritisation of activities. Increasingly, this is enabled by agentic AI — systems that can assist with coordinating defined tasks and workflows, while remaining under expert human oversight.
Trial close‑out
ICON is applying automation and AI assistance to areas such as data processing, analysis outputs, and draft report generation. These capabilities, which continue to evolve, are focused on shortening timelines from database lock to submission while preserving data quality, traceability, and regulatory compliance.
Orbis agentic AI
Orbis is ICON’s multi-agent agentic AI framework and agent services platform, powering a connected ecosystem of AI agents across teams, processes and technology.
Governance and trust as standard
Our AI ethics committee, compliance rigor, and data privacy framework are not add-ons. They are the foundation. In a regulated industry, the confidence to act on AI-generated insights depends entirely on whether those insights can be trusted, traced, and defended. ICON's governance infrastructure gives you that assurance.
One Search
ICON’s AI-powered site selection tool that analyses extensive data to find the best sites quickly; reduces time to identify sites by ~53% and cuts non-enrolling sites by up to 50%.
ICONex
Visualises expert networks and key opinion leaders, particularly for rare diseases, speeding up protocol design and feasibility planning.
Cassandra
Uses AI and ML on real-world post-marketing requirements data from FDA and EMA to predict postmarketing requirements as early as Phase I with ~99% accuracy.
iSubmit
AI-driven automation for eTMF filing and document management, reducing administrative burden, improving indexing, and cutting audit findings.
MRT COA
An AI-powered outcomes intelligence tool that auto-updates the eCOA database in near real-time using NLP and fine-tuned large language models, supporting outcomes strategy.
FORWARD+
AI-enabled resource forecasting capability that promotes efficient management of staff and operational resources throughout the trial lifecycle.
SmartDraft
SmartDraft is our AI-powered solution that transforms one of the most time-consuming and manual aspects of study start-up. By learning from thousands of historical contracts, IT streamlines precedent selection, accelerates negotiations, and reduces the friction in global site contracting.
OMR AI Navigation Assistant
A generative-AI-enabled analytics assistant that transforms operational clinical metrics into actionable business insights for smarter decision-making.
EngageAI
EngageAI transforms collated customer feedback into structured reports at unprecedented speed and scale. It summarises feedback, analyses sentiment, and identifies key themes.
AI blogs and media articles
-
Media article: The CRA role’s co-evolution with clinical trial technology
As clinical trials become more complex, the role of the CRA is evolving from site monitor to strategic, digitally fluent partner, requiring expertise in hybrid oversight, risk-based monitoring, and multi-system data management.
-
Media article: Bold moves
CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. ICON explores what this means for the future in Pharma Times.
-
Media article: Regulatory strategy reimagined: Three trends accelerating drug development
The regulatory landscape is being rewritten. The future belongs to those who anticipate, adapt and act with purpose. In this article we look at 3 macro trends that are redefining regulatory strategy.
-
Media article: Precision medicine meets machine learning: AI and oncology biomarkers
AI is redefining oncology biomarker discovery, unlocking new precision in patient selection and trial design. Explore how this evolving technology is shaping the future of cancer drug development.
-
Media article: Smarter starts, stronger trials: How data is driving faster site activation
Feasibility, site selection and study startup are among the most complex areas of clinical development, yet they remain stubbornly inefficient. ICON’s Brian Mallon explores how sponsors and CROs are leveraging AI, predictive analytics and integrated data environments for faster, more predictable trial delivery and stronger site partnerships. Read the full article.
-
Media article: Beyond approval
In the October issue of PharmaTimes, Dr. Quintin van Wyk considers the importance of post-marketing pharmacovigilance, and explains how carefully applied automation and AI can strengthen adverse event reporting and causality assessment while keeping patient safety and regulatory compliance central.
-
Media article: ICON’s new CEO champions AI and efficiency during industry’s ‘pivotal time’
ICON's new CEO, Barry Balfe, speaks to BioXconomy on industry challenges - and opportunities - ahead.
-
Media article: Navigating global regulatory expectations for AI-enabled devices
Despite the increasing use of AI in medical devices and software as medical devices (SaMD), global regulatory authorities are playing catch up to develop appropriate submission channels. Read the article in Med-Tech Insights.
AI whitepapers
Get started with AI at ICON
Ready to transform your clinical trials with AI? Contact us today to learn how ICON's AI solutions can accelerate your research and deliver better outcomes.